FDA
-
-
-
-
-
-
-
REGENXBIO reports interim data for Duchenne gene therapy RGX-202
-
-
-
-
-
-
-
REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
-
-
-
-
-
-
-
REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
-
-
-
-
-
-
-
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program
-
-
-
-
-
-
-
REGENXBIO reports sustained biomarker reduction in MPS II gene therapy trial
-
-
-
-
-
-
-
REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

